Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Samsung Shares Rise on $72 Billion Shareholder Return Plan 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3 
Coty Revenue Beats Estimates as Beauty Demand Holds Firm 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Welspun Corp Shares Hit Record High on $1.8 Billion U.S. Order 
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports 
OpenAI Tightens AI Safety Monitoring After Security Incidents 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
REPAY Stock Rises After Visa Platform Connect Collaboration 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
Alibaba Shares Fall as AI Spending Hits Profit 
(4) - EconoTimes)
Add as a preferred source on Google
CHESTERBROOK, Pa., May 08, 2018 -- Trevena, Inc. (NASDAQ:TRVN) today announced that the independent Compensation Committee of the Board of Directors of the Company approved, effective as of May 2, 2018, the grant of inducement stock options to purchase 27,000 shares of the Company's common stock to Richard Zimet, a new employee. These awards were granted pursuant to the Trevena, Inc. Inducement Plan as an inducement material to the new employees entering into employment with the Company, in accordance with NASDAQ Listing Rule 5635(c)(4).
The stock option has an exercise price per share of $2.07, the closing stock price on May 2, 2018. The option has a ten-year term and will vest with respect to one-sixteenth of the total number of shares subject to the option on each quarterly anniversary of the grant date.
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on providing better, safer therapies to patients in pain. The Company has leveraged breakthrough science to discover and develop its investigational product, oliceridine injection, for the management of moderate-to-severe acute pain. Oliceridine has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration, and is intended to provide healthcare providers an innovative new option for patients who require an intravenous opioid. The Company also has an early stage pipeline of new chemical entities targeting novel mechanisms of action, including TRV250 for acute migraine, neuropathic pain, and other indications.
Contacts
Trevena, Inc.
Investors:
Jonathan Violin, Ph.D.
SVP, scientific affairs and investor relations officer
610-354-8840 x231
[email protected]
or
Media:
Public Relations
[email protected]
